Summary:
We describe a patient with left branch portal vein thrombosis involving two thrombophilic alterations, the prothrombin G20210A mutation and protein C deficiency. In spite of not being under anticoagulant treatment, the thrombus in the portal vein underwent complete and spontaneous lysis. No other risk factors were detected and no family history related to thrombosis was found. Key Words: Portal vein thrombosis&mdash; Vein thrombosis&mdash;Prothrombin G20210A&mdash;Protein C deficiency.
CASE REPORT
The causes of portal vein thrombosis include myeloproliferative disorders, intrabdominal neoplasia or infection, liver biopsy, splenectomy, and cirrhosis (1, 2) . Recent reports have described its association with deficiencies of natural anticoagulants such as protein C (3-6), protein S (5-7), heparin cofactor II(8), and antithrombin (9) . Association with the antiphospholipid antibody syndrome and factor V Leiden mutation has also been described (8, (10) (11) (12) (13) (14) . However, despite full clinical and laboratory investigation, the underlying etiology is not always identified.
Recently a novel mutation in the 3' untranslated region of the prothrombin gene (20210 G to A) associated with high levels of prothrombin has been reported to be a risk factor for venous thrombosis. It is being present in about 6% of patients with deep-vein thrombosis and 2% of the controls (15) . Association between this mutation and the presence of idiopathic portal vein thrombosis has been described previously in a study with a small number of patients (16) .
The present report describes, for the first time to our knowledge, a patient presenting portal vein thrombosis associated to heterozygous prothrombin G20210A mutation and protein C deficiency.
A 39-year-old man complained with of epigastric pain lasting 4 days. This pain, which was not accompanied by flatulence, changes in feces, or food intake, irradiated out towards the right hypochondrium and was exacerbated by movement. He did not complain of nausea and vomiting and showed no changes in intestinal function. On physical examination there were no signs of ascites or hepatosplenomegaly. Colateral circulation was not detected. The abdomen was soft, and pressure on the epigastrium or hypochondrium caused pain. Predisposing factors in relation with vein thrombosis were not associated. The laboratory biochemical tests, routine hematological profile, and hemostatic analysis (prothrombin time, thrombin time, and fibrinogen) gave results in the normal range. Magnetic resonance imaging (Fig. 1 ) showed thrombosis in the left branch of the portal vein. At that point in time, the patient was not receiving anticoagulant treatment. At I month later, hepatobiliary gamma radiography with iminodiacetic acid (IDA) and an abdominal ecograph showed that the thrombi had undergone complete lysis. At 3 months after the acute event, the patient was referred to our unit for an evaluation of his hypercoagulable state. Antithrombin, protein C, protein S, cofactor II heparin, prothrombin G20210A, APC-R, Factor V Leiden, type 1 plasminogen activator inhibitor, and anticardiolipin antibodies were tested. A genotype heterozygous for the prothrombin G20210A and a protein C deficiency (56%) were found. At 7 months later, the patient showed clinical symp- toms of a possible vein thrombosis. However, this was ruled out by ultrasonography, and a diagnosis of superficial phlebitis was reached. Since then, the patient has been under treatment with acenocoumarol international normalized ratio (INR) 2-3 as a secondary prophylaxis for a possible rethrombosis, and will continue to be treated with it for an undetermined period of time.
The family's test results were negative for documented thrombotic events. The patient's parents were not available for testing. A study run on his two siblings and his two daughters showed that his sister was carrier of prothrombin G20210A mutation and one of his daughters had a protein C deficiency (62%). The prothrombin G20210A mutation has only sporadically been described in association with idiopathic portal vein thrombosis (16) . Because no additional thrombotic risk factors were found in our patient, it may be that the copresence of prothrombin G20210A mutation and protein C deficiency contributes to the portal vein thrombosis. The high prevalence of the prothrombin G20210A mutation in the healthy white population may make it obligatory to consider this disorder in young patients (<45 years of age) with portal vein thrombosis, especially in those without predisposing risk factors.
